U.S. markets closed

How Does Investing In ENDRA Life Sciences Inc. (NASDAQ:NDRA) Impact The Volatility Of Your Portfolio?

Simply Wall St

If you own shares in ENDRA Life Sciences Inc. (NASDAQ:NDRA) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of volatility. Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. The first type is company specific volatility. Investors use diversification across uncorrelated stocks to reduce this kind of price volatility across the portfolio. The second sort is caused by the natural volatility of markets, overall. For example, certain macroeconomic events will impact (virtually) all stocks on the market.

Some stocks see their prices move in concert with the market. Others tend towards stronger, gentler or unrelated price movements. Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). While we should keep in mind that Warren Buffett has cautioned that 'Volatility is far from synonymous with risk', beta is still a useful factor to consider. To make good use of it you must first know that the beta of the overall market is one. Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

See our latest analysis for ENDRA Life Sciences

What we can learn from NDRA's beta value

Given that it has a beta of 1.79, we can surmise that the ENDRA Life Sciences share price has been fairly sensitive to market volatility (over the last 5 years). Based on this history, investors should be aware that ENDRA Life Sciences are likely to rise strongly in times of greed, but sell off in times of fear. Beta is worth considering, but it's also important to consider whether ENDRA Life Sciences is growing earnings and revenue. You can take a look for yourself, below.

NasdaqCM:NDRA Income Statement, March 11th 2020

Could NDRA's size cause it to be more volatile?

With a market capitalisation of US$8.7m, ENDRA Life Sciences is a very small company by global standards. It is quite likely to be unknown to most investors. It has a relatively high beta, suggesting it is fairly actively traded for a company of its size. Because it takes less capital to move the share price of a small company like this, when a stock this size is actively traded it is quite often more sensitive to market volatility than similar large companies.

What this means for you:

Since ENDRA Life Sciences has a reasonably high beta, it's worth considering why it is so heavily influenced by broader market sentiment. For example, it might be a high growth stock or have a lot of operating leverage in its business model. In order to fully understand whether NDRA is a good investment for you, we also need to consider important company-specific fundamentals such as ENDRA Life Sciences’s financial health and performance track record. I urge you to continue your research by taking a look at the following:

  1. Future Outlook: What are well-informed industry analysts predicting for NDRA’s future growth? Take a look at our free research report of analyst consensus for NDRA’s outlook.
  2. Financial Health: Are NDRA’s operations financially sustainable? Balance sheets can be hard to analyze, which is why we’ve done it for you. Check out our financial health checks here.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.